Identification and characterization of S6K1 targets in mammary cell proliferation

Information

  • Research Project
  • 7939124
  • ApplicationId
    7939124
  • Core Project Number
    R15CA151112
  • Full Project Number
    1R15CA151112-01
  • Serial Number
    151112
  • FOA Number
    RFA-OD-09-007
  • Sub Project Id
  • Project Start Date
    6/1/2010 - 14 years ago
  • Project End Date
    6/30/2013 - 11 years ago
  • Program Officer Name
    KNOWLTON, JOHN R.
  • Budget Start Date
    6/1/2010 - 14 years ago
  • Budget End Date
    6/30/2013 - 11 years ago
  • Fiscal Year
    2010
  • Support Year
    1
  • Suffix
  • Award Notice Date
    5/30/2010 - 14 years ago
Organizations

Identification and characterization of S6K1 targets in mammary cell proliferation

DESCRIPTION (provided by applicant): S6 kinase 1 (S6K1) is an important regulator of cell size control, protein translation and cell proliferation, and one of the best-characterized downstream targets of the mammalian Target of Rapamycin (mTOR). RPS6KB1, the gene encoding S6K1, is amplified in up to 30% of breast cancers. S6K1 is over expressed in the majority of cases with RPS6KB1 amplification. Over-expression of S6K1 correlates with poor prognosis in breast cancer patients. S6K1 also mediates rapamycin sensitivity of breast cancer cells. The specific aims are designed to provide a comprehensive assessment of the therapeutic potential of the S6K1 signaling pathway by identifying and characterizing downstream effectors of S6K1 in breast cancer cells. The specific aims of this proposal focus on the mechanism by which S6K1 controls cell proliferation by identifying breast cancer cell specific S6K1 effectors. In Aim 1, we propose a biochemical approach coupled with mass spectrometry for identification of novel substrates of S6K1. In Aim 2, we will characterize S6K1 substrate proteins, and will map rapamycin-sensitive phosphorylation sites. In Aim 3, we will study the role of S6K1 substrates in control of breast cell proliferation. The proposed work will facilitate subsequent development of new inhibitors of S6K1 and its downstream effectors in treatment of tumors with S6K1 amplification. PUBLIC HEALTH RELEVANCE: Breast cancer is the second leading cause of cancer death in women. Current chemotherapies are indiscriminate, have toxic side effects, and in 45% of patients do not prevent cancer progression or recurrence. The experiments described in this proposal will allow us to comprehensively evaluate the role of S6K1 as a breast cancer oncogene and its therapeutic potential in the treatment of this disease.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R15
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    408400
  • Sub Project Total Cost
  • ARRA Funded
    True
  • CFDA Code
    701
  • Ed Inst. Type
    SCHOOLS OF ARTS AND SCIENCES
  • Funding ICs
    OD:408400\
  • Funding Mechanism
    Research Projects
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    YESHIVA UNIVERSITY
  • Organization Department
    BIOLOGY
  • Organization DUNS
    071036636
  • Organization City
    NEW YORK
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    100333201
  • Organization District
    UNITED STATES